Last updated on March 2017

Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)


Brief description of study

The primary objective of this first in human study is to assess the safety and tolerability of increasing intravenous (IV) doses of single agent IPH4102 administered to patients with relapsed/refractory CTCL to characterize the dose limiting toxicities (DLT) and identify a Maximum Tolerated Dose (MTD).

Clinical Study Identifier: NCT02593045

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Youn KIM, MD

Stanford Cancer Center
Stanford, CA United States
  Connect »

Basem WILLIAM, MD

Ohio State University
Columbus, OH United States
  Connect »

Martine BAGOT, MD

H pital Saint-Louis
Paris, France
  Connect »

Maarten VERMEER, MD

Leiden University Medical Center
Leiden, Netherlands
  Connect »

Sean WHITTAKER, MD

Guy's Hospital
London, United Kingdom
  Connect »